A clinical team has spearheaded the use of CAR-T cell therapy for blood cancers. The researchers recently treated the first ...

Chimeric antigen receptor T (CAR-T) Cell therapy has emerged, and now the structure of CAR has changed from first generation to fourth generation of CAR. The significant achievement of CAR-T therapy ...

Engineering a patient's own T cells to express chimeric antigen receptors (CARs) has cured patients with cancer refractory to all treatments. Decades ago, as this modality was being developed, there ...

aCenter for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA bDepartment of Pathology and Laboratory Medicine, University of Pennsylvania ...

Department of Biomedical Engineering, State University of New York at Buffalo, Buffalo, New York 14260, United States ...

A patient has achieved over 18 years of remission from neuroblastoma, a type of nerve cell cancer, following treatment with chimeric antigen receptor (CAR) T cell therapy and without requiring any ...

The research team hypothesized that binding of the antigen to the T-cell receptor would cause a conformational change, allowing it to initiate a downstream signaling cascade. By comparing an ...

Despite advances in therapies, the prognosis of lung cancer has not been substantially improved in recent years. Chimeric antigen receptor (CAR)-T cell immunotherapy has attracted growing interest in ...

Generation of high-affinity, protective antibodies requires B cell uptake of antigens via their antigen-specific B cell receptors (BCRs). After antigen binding, the BCR undergoes endocytosis and ...